Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

Assessment of KRAS status is mandatory in patients with metastatic colorectal cancer (mCRC) before applying targeted therapy. We describe here a blinded prospective study to compare KRAS and BRAF mutation status data obtained from the analysis of tumor tissue by routine gold-standard methods and of plasma DNA using a quantitative PCR–based method specifically designed to analyze circulating cell-free DNA (cfDNA). The mutation status was determined by both methods from 106 patient samples. cfDNA analysis showed 100% specificity and sensitivity for the BRAF V600E mutation. For the seven tested KRAS point mutations, the method exhibited 98% specificity and 92% sensitivity with a concordance value of 96%. Mutation load, expressed as the proportion of mutant alleles in cfDNA, was highly variable (0.5–64.1%, median 10.5%) among mutated samples. CfDNA was detected in 100% of patients with mCRC. This study shows that liquid biopsy through cfDNA analysis could advantageously replace tumor-section analysis and expand the scope of personalized medicine for patients with cancer.

[1]  H. Grabsch,et al.  The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients , 2010, British Journal of Cancer.

[2]  R. McManus,et al.  A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up , 2003 .

[3]  M. Ychou,et al.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts , 2010, Nucleic acids research.

[4]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[5]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[7]  I. Cree,et al.  Circulating tumour markers can define patients with normal colons, benign polyps, and cancers , 2011, British Journal of Cancer.

[8]  S. Goodman,et al.  Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. , 2008, Gastroenterology.

[9]  Niels Pallisgaard,et al.  Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan , 2012, Clinical Cancer Research.

[10]  Francisco M. De La Vega,et al.  Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2010, Science Translational Medicine.

[11]  I. Nagtegaal,et al.  KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients , 2011, British Journal of Cancer.

[12]  J. Reid,et al.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Mouliere,et al.  The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients , 2012, Expert opinion on biological therapy.

[14]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[15]  Yoko Yamamoto,et al.  The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. , 2010, Biochemical and biophysical research communications.

[16]  P. Lamy,et al.  KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment , 2012, Modern Pathology.

[17]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[18]  L. Peloso,et al.  Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. , 2006, The International journal of biological markers.

[19]  Dermot Kelleher,et al.  A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up , 2003, Gut.

[20]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Kaneko,et al.  KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab , 2011, British Journal of Cancer.

[22]  M. Ychou,et al.  High Fragmentation Characterizes Tumour-Derived Circulating DNA , 2011, PloS one.

[23]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[24]  M. Ranson,et al.  Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer , 2010, Breast Cancer Research and Treatment.

[25]  M. Stroun,et al.  Isolation and characterization of DNA from the plasma of cancer patients. , 1987, European journal of cancer & clinical oncology.

[26]  Jaw-Yuan Wang,et al.  Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.

[27]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[28]  Bruno Landi,et al.  Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis , 2002, International journal of cancer.

[29]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[30]  J. Solassol,et al.  KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues , 2011, International journal of molecular sciences.

[31]  M. Ychou,et al.  Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[33]  R. Henrique,et al.  Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. , 2011, Cancer genetics.

[34]  A. Lièvre,et al.  Review of the current status of KRAS mutation testing in France in 2011: The Flash-KRAS study. , 2012 .

[35]  W. Weichert,et al.  KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. , 2010, The Journal of molecular diagnostics : JMD.

[36]  Colin C Pritchard,et al.  Colorectal cancer molecular biology moves into clinical practice , 2010, Gut.

[37]  T. Frebourg,et al.  Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer , 2010, Annals of surgery.

[38]  H. Lee,et al.  Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer , 2012, BMC Cancer.

[39]  Calum MacAulay,et al.  Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells , 2009, PloS one.

[40]  F. López-Ríos,et al.  A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens , 2012, British Journal of Cancer.

[41]  T. Eberlein.  Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status , 2012 .

[42]  O. Nordgård,et al.  Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy , 2011, International Journal of Colorectal Disease.

[43]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.